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metabolic pathways in the induction of cell lethality in
L1210 leukaemia
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Laboratory for Chemotherapy, Department ofPharmacology, Vrie Universiteit Brussel, B-1090 Brussels,
Belgium.
Summary The mode of action of 5-fluorouracil (FUra) and 5-fluoro-2'-deoxyuridine (FdUrd) on L1210
leukaemia has been studied. It is shown that FUra and FdUrd follow different routes of metabolism and have
different targets with respect to their cytotoxic activity. FUra is converted to 5-fluorouridine-5'triphosphate
(FUTP), which is incorporated into nascent RNA. FdUrd is converted to 5-fluoro-2'-deoxyuridine-5'-
monophosphate (FdUMP), which inhibits the de novo synthesis of 2'-deoxythymidine-5'-monophosphate
(dTMP). Conversion of FUra to FdUMP does occur, but this phenomenon does not contribute to the final
cytotoxic effect. No conversion of FdUrd to FUra has been detected.
Fluoropyrimidines are widely used in anti-cancer
chemotherapy and are probably the drugs whose
mechanism of activity is best understood
(Heidelberger, 1975). Essentially, two processes
are involved in the cytotoxic activity of
fluoropyrimidines. First, dTMP depletion may
occur due to the inhibition of thymidilate
synthetase by FdUMP. Second, fluoropyrimidine
analogues can be incorporated into nascent RNA
resulting in defective RNA species (Heidelberger,
1975). The enzymatic processes converting FUra
and FdUrd to the active nucleotide forms are
summarised in Figure 1. Briefly, FdUrd can be
directly phosphorylated to FdUMP which inhibits
thymidilate synthetase (Hartman & Heidelberger,
1961). By another pathway FdUrd can be degraded
to FUra by thymidine phosphorylase (Skold, 1960;
Woodman et al., 1980). Formation of 5-
fluorouridine-5'-monophosphate (FUMP) can occur
directly via a phosphoribosyl-transferase-mediated
phosphoribosylation (Reyes, 1969) or a two step
process involving uridine phosphorylase and uridine
kinase (Skold, 1958). Subsequent phosphorylation
of FUMP leads to the formation of FUTP
(Chauduri et al., 1958), which can be incorporated
into nascent RNA (Wilkinson & Pitot, 1973).
Alternatively, the intermediate 5-fluorouridine-5'-
diphosphate (FUDP) can be degraded to 5-fluoro-
2'-deoxyuridine-5'-diphosphate (FdUDP) by ribo-
nucleotide reductase (Kent & Heidelberger, 1972).
Dephosphorylation of this FdUDP leads to the
formation of FdUMP (Cohen et al., 1958). Finally,
FdUDP can be phosphorylated to 5-fluoro-2'-
deoxyuridine-5'-triphosphate (FdUTP) which can
be incorporated into nascent DNA (Kufe et al.,
1981).
Despite the extensive literature on this subject,
less certainty exists with respect to which pathway
is followed by the respective fluoropyrimidines or
which target is decisive for cytotoxicity. The
incorporation of FUra into RNA has been reported
for a variety of animal and human cell lines (Glazer
& Legraverend, 1980; Glazer & Hartman, 1979;
Glazer & Peale, 1979; Major et al., 1982; Wilkinson
& Pitot, 1973) and has been correlated with its
cytotoxic effect (Kufe & Major, 1981). For other
cells, thymidylate synthetase has been reported to
be the primary target for fluoropyrimidines, whilst
the incorporation into nascent RNA was considered
to be a second site effect (Ardalan et al., 1978;
Spears et al., 1982).
In this study, we describe a procedure to rapidly
identify the target for the cytotoxic action
fluoropyrimidines. Using this technique, it was
shown that in L1210 leukaemia FUra and FdUrd
follow different metabolic pathways leading to the
incorporation into nascent RNA and the inhibition
of de novo thymidylate synthesis respectively,
without the occurrence of any interconversion
which contributes to the final cytotoxic effect.
Materials and methods
Reagents
ICH3-3HIdThd (sp. act. 8OCimmol-1) and 16- HIdUrd (sp. act. 26Cimmol-1) were obtained
from New England Nuclear, Boston, Ms, USA.
Unlabelled dThd, dUrd, FUra and FdUrd were
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Figure 1 Metabolic pathways of fluoropyrimidines. dThd kinase =thymidine kinase; dThd
phosphorylase =thymidine phosphorylase; dTMP synthetase =thymidylate synthetase; NDP
reductase =nucleoside diphosphate reductase; NDP kinase =nucleoside diphosphate kinase; NMP
kinase =nucleoside monophosphate kinase; Urd kinase =uridine kinase; Urd phosphorylase =uridine
phosphorylase; RP transferase =phosphoribosyl transferase.
products of the Sigma Chemical Company, St.
Louis, Mi, USA. Medium RPMI 1640 was
purchased from Gibco Europe, Paisley, U.K. All
other chemicals were reagent grade.
Cell culture
L1210 leukaemic cells were grown in suspension in
RPMI 1640 medium, supplemented with 10% (v/v)
foetal calf serum. The effect of FdUrd or FUra on
cell proliferation was measured as follows. L1210
leukaemia cells (5 x 103) were incubated in 150,u1 of
RPMI 1640 medium, supplemented with 10% (v/v)
foetal calf serum in the continuous presence of
antimetabolites and nucleosides as indicated in the
legends to the Figures. After a period of 3 days at
37°C in a humidified 5% (v/v) CO2 atmosphere, the
increase in cell number was determined with a
Neubauer counting chamber. Test results are the
mean of quadruplicate incubations with an average
s.d. of 8%.
Precursor incorporation
L1210 leukaemic cells (5 x 104) were incubated in
lOO1 u1 of medium RPMI 1640, supplemented with
10% (v/v) foetal calf serum in the presence of
varying amounts of I3HIdThd or 13HIdUrd and in
the presence or absence of varying amounts of anti-
metabolites, as indicated in the legends to the
Figures. After an incubation of 2h at 37°C in a
humidified 5% (v/v) CO2 atmosphere, the cells were
collected on glass fiber filters and the amount of
radioactivity retained was determined. Test results
are the mean of quadruplicate incubations with an
average s.d. of 6%.
Results
Thymidylate synthetase, the enzyme responsible for
the de novo synthesis of thymidine monophosphate,
has since long been known to be a target for the
action of fluoropyrimidines (Heidelberger, 1975).
C1)
co
0
0. C,,
0
-C
0.
FUra
CA n
E
z
a
F-DNA
n
Co 0
Q 0.
z
._~~~~~~~~~~~~~~~~~~c
F-RNA
11
I
l
IMODE OF ACTION OF FLUOROPYRIMIDINES 741
The interference of fluoropyrimidines with thymidy-
late synthetase can be visualised by their effect on
the incorporation of tritiated thymidine (dThd) into
nascent DNA (Naaktgeboren et al., 1983). In the
absence of antimetabolites, DNA thymine will in
part be unlabelled, derived from de novo synthesis,
and in part labelled, derived from the exogenous
pool of thymidine and incorporated via the salvage
pathway. In case de novo thymidylate synthesis is
blocked, all DNA thymine will be derived from the
salvage pathway, hence resulting in an increase in
the level of 13HjdThd incorporation. As confirmed
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in Figure 2, both FdUrd and FUra were able to
block thymidylate synthesis at concentrations of
10-6M and 10-4M, respectively. If thymidylate
synthetase is the predominant target with respect to
the action of these antimetabolites, rescue from
fluoropyrimidine intoxication should be achieved
upon addition of thymidine, in which case the
blockade of thymidylate synthetase could be
circumvented via the salvage pathway. A significant
rescue was observed in case of FdUrd (Figure 3a),
whereas thymidine had no observable effect on the
cytotoxicity of FUra (Figure 3b), even at concen-
b
IU
[3H]-dThd, pM
Figure 2 The incorporation of (3H)dThd into nascent L1210 leukaemia DNA was measured both in the
absence (0) and presence (0) of either 10-6 M FdUrd (a) or 10- M FUra (b).
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Figure 3 L1210 leukaemia cells were grown in the presence of varying concentrations of FdUrd (a) or 5FU
(b), both in the presence (0) or absence (0) of 5 x 10-6M dThd. The extent of proliferation is given as a
percentage of the untreated control.
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trations where complete rescue from FdUrd toxicity
was achieved (Figure 4).
These experiments suggest, firstly, that
thymidylate synthetase is indeed the main target for
FdUrd and, secondly, that de novo thymidylate
synthesis, although inhibited by saturating concen-
trations of FUra is not involved in its cytotoxic
effect. Obviously, FdUrd and FUra must follow
different metabolic pathways. To corroborate this
point, the effects of FdUrd and FUra on de novo
thymidylate synthesis were studied in more detail. If
thymidylate synthetase is the principal target for
the action of fluoropyrimidines, the inhibition of de
novo thymidylate synthesis, as measured via 2'-
deoxyuridine (dUrd) incorporation, would be
expected to coincide with the inhibition of cell
proliferation. This was indeed the case for FdUrd,
as shown in Figure 5a. However, a different result
was obtained for FUra (Figure 5b). Inhibition of
cell proliferation was complete at concentrations of
FUra at which no significant decrease in the level
of 13HjdUrd incorporation could be observed. In
order to confirm that the fluoropyrimi-
dine-dependent inhibition of I3HIdUrd incor-
poration did occur at the level of thymidylate
synthetase an identical experiment was performed
using changes in the incorporation of tritiated
thymidine as a measure of de novo thymidylate
synthesis (cf. Figure 2). As shown in Figure 6a, the
increase in thymidine incorporation as a function of
the FdUrd concentration coincided with the anti-
proliferative effect of FdUrd. However, in the case
of FUra, the concentration required to achieve an
increase in the incorporation of I3HIdThd was two
logs above the concentration that sufficed for
growth inhibition.
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Figure 4 The cytotoxic effect of FdUrd (0) and FUra
(0) on L1210 leukaemia was measured as described in
the legend to Figure 3. in the presence of varying
concentrations of dThd. The IC50 is defined as the
concentration of antimetabolite which leads to a 50%
inhibition of cell growth as compared to the untreated
control.
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Figure 5 The incorporation of [3H]dUrd into nascent L1210 leukaemia DNA (0) was measured in the
presence of varying concentrations of FdUrd (a) or FUra (b) and compared with the effects on L1210
leukaemia proliferation (0) redrawn from Figure 3.
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Figure 6 The incorporation of [3H]dThd into nascent
L1210 leukaemia DNA (0) was measured in the
presence of increasing concentrations of FdUrd (a) or
5FU (b) and compared with the effects on L1210
leukaemia proliferation (40) redrawn from Figure 3.
Discussion
The results presented in this study justify the
following conclusions with respect to the mode of
action of fluoropyrimidines on L1210 leukaemia.
First, de novo thymidylate synthesis is the principal
target for FdUrd activity. Following trans-
membrane transport FdUrd is phosphorylated to
FdUMP, which in the presence of methylene tetra-
hydrofolic acid binds to thymidylate synthetase,
resulting in the formation of an inactive ternary
complex (Danenberg, 1977). Second, no effective
nucleoside phosphorylase mediated degradation of
FdUrd to FUra occurs, as judged by the
observation that complete rescue from FdUrd
toxicity can be achieved upon addition of dThd and
that inhibition of de novo thymidylate synthesis
coincides perfectly with growth inhibition. Third,
thymidylate synthetase inhibition is not involved in
the action of FUra as judged by the observations
thlat no rescue from FUra toxicity can be achieved
upon addition of dThd and that growth inhibition
ic complete at concentrations of FUra at which no
inhibition of thymidylate synthesis can be observed.
Fourth, conversion of FUra to FdUMP does
occur, but this conversion does not contribute to
the cytotoxic effect of FUra.
It should be noted that these observations have
been made for L1210 leukaemia and are not
necessarily valid for other cell lines. Different
routes of metabolism of FUra have been reported
(Laskin & Hakala, 1977; Mandel, 1981; Piper &
Fox, 1982), suggesting that the route of metabolism
of fluoropyrimidines is an individual characteristic
of tumours. The metabolic processing of fluoro-
pyrimidines which precedes their cytotoxic action
has been suggested to allow a simple prediction of
the therapeutic efficacy of fluoropyrimidines
(Ardalan et al., 1978, 1981; Kufe & Major, 1981).
However, the present study shows that FUra and
FdUrd do not necessarily act on the same target.
Therefore, studies on their route of metabolism
seem unlikely to be sufficient in predicting cyto-
toxicity if the targets are not identified. In this
context, the methodology described in this study
may contribute to the development of reliable
predictive assays for the efficacy of fluoro-
pyrimidines.
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